Attralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL Amyloidosis

Regulatoryzamubafusp alfaPositive

AI Analysis

Summary

Attralus announced that the FDA has granted Fast Track designation for zamubafusp alfa (AT-02) for the treatment of light chain (AL)-associated amyloidosis, a rare and progressive condition. Fast Track status accelerates the development and review timeline for this investigational therapeutic.

Outcome Details

Fast Track designation granted

Importance:6/10

Sentiment:

0.80

Fast Track DesignationFDA RegulatoryRare DiseaseAmyloidosisClinical Stage

Read the original article

Published by GlobeNewswire Clinical Studies on August 12, 2026 11:00 AM

Read Original